Yves Juillière1, Christine Suty-Selton2, Elisabeth Riant2, Jean-Pierre Darracq3, Arnaud Dellinger4, Jean-Philippe Labarre5, Justine Druelle6, Geneviève Mulak7, Nicolas Danchin8, Patrick Jourdain9. 1. Cardiology Department, institut Lorrain du coeur et des vaisseaux, allée du Morvan, 54500 Vandœuvre-lès-Nancy, France. Electronic address: y.juilliere@chu-nancy.fr. 2. Cardiology Department, institut Lorrain du coeur et des vaisseaux, allée du Morvan, 54500 Vandœuvre-lès-Nancy, France. 3. Cardiology, CHG Samuel-Pozzi, Bergerac, France. 4. Cardiology, CHG William-Morey, Chalon-sur-Saône, France. 5. Cardiology, clinique Château-de-Vernhes, Bondigoux, France. 6. URC-Est, CHU Saint-Antoine, Paris, France. 7. French Society of Cardiology, Paris, France. 8. Cardiology, European Hospital Georges Pompidou, Paris, France. 9. Cardiology, CHG René-Dubos, Pontoise, France.
Abstract
BACKGROUND: Chronic heart failure (CHF) is a frequent severe disease. Disease-management programmes, which contain a therapeutic patient education component, will play a central role in improving delivery of care and reducing mortality and hospitalizations for CHF. AIMS: In order to have an up-to-date overview of medical treatment of CHF in France implemented by hospital and clinic cardiologists especially interested in CHF and therapeutic patient education, we described the prescription of cardiovascular drugs in the large ODIN cohort of CHF patients, according to age and type of CHF. METHODS: From 2007 to 2010 (median follow-up 27.2 months), CHF patients were prospectively enrolled in a multicentre 'real-world' French cohort by centres previously trained in therapeutic patient education. Patients were grouped according to age (< 60 years, 60 to<70 years, 70 to<80 years and ≥ 80 years) and type of CHF (characterized by level of LVEF: reduced, borderline or preserved). Medical prescription was described and mortality was assessed at long-term follow-up. RESULTS: The cohort consisted of 3237 patients (67.6 years; 69.4% men). The oldest age group had the highest LVEF. Blockers of the angiotensin-aldosterone system were prescribed progressively and significantly less frequently as the population advanced in age or as LVEF was more preserved. The mean dosages of the main prescribed CHF drugs remained ≥ 50% lower than those recommended for most drugs in all age and LVEF groups. Drug prescriptions were related to aetiology of reduced or preserved CHF. A global decrease in CHF drug prescription was observed for all medication classes except calcium blockers, according to maintenance of relatively or totally preserved LVEF. Survival was related to age but not to type of CHF. CONCLUSION: In CHF, and despite management by cardiologists particularly interested in CHF and specifically trained to deliver therapeutic patient education, medical prescription differed substantially from guidelines. Age and type of CHF (reduced versus preserved) appeared to be important factors in lack of adherence to guidelines. However, only age influenced mortality; the type of CHF did not affect survival.
BACKGROUND:Chronic heart failure (CHF) is a frequent severe disease. Disease-management programmes, which contain a therapeutic patient education component, will play a central role in improving delivery of care and reducing mortality and hospitalizations for CHF. AIMS: In order to have an up-to-date overview of medical treatment of CHF in France implemented by hospital and clinic cardiologists especially interested in CHF and therapeutic patient education, we described the prescription of cardiovascular drugs in the large ODIN cohort of CHFpatients, according to age and type of CHF. METHODS: From 2007 to 2010 (median follow-up 27.2 months), CHFpatients were prospectively enrolled in a multicentre 'real-world' French cohort by centres previously trained in therapeutic patient education. Patients were grouped according to age (< 60 years, 60 to<70 years, 70 to<80 years and ≥ 80 years) and type of CHF (characterized by level of LVEF: reduced, borderline or preserved). Medical prescription was described and mortality was assessed at long-term follow-up. RESULTS: The cohort consisted of 3237 patients (67.6 years; 69.4% men). The oldest age group had the highest LVEF. Blockers of the angiotensin-aldosterone system were prescribed progressively and significantly less frequently as the population advanced in age or as LVEF was more preserved. The mean dosages of the main prescribed CHF drugs remained ≥ 50% lower than those recommended for most drugs in all age and LVEF groups. Drug prescriptions were related to aetiology of reduced or preserved CHF. A global decrease in CHF drug prescription was observed for all medication classes except calcium blockers, according to maintenance of relatively or totally preserved LVEF. Survival was related to age but not to type of CHF. CONCLUSION: In CHF, and despite management by cardiologists particularly interested in CHF and specifically trained to deliver therapeutic patient education, medical prescription differed substantially from guidelines. Age and type of CHF (reduced versus preserved) appeared to be important factors in lack of adherence to guidelines. However, only age influenced mortality; the type of CHF did not affect survival.
Authors: Lisa C Bratzke; Debra K Moser; Michele M Pelter; Steven M Paul; Thomas S Nesbitt; Lawton S Cooper; Kathleen A Dracup Journal: J Cardiovasc Nurs Date: 2016 Jan-Feb Impact factor: 2.083
Authors: Camille Roubille; Benjamin Eduin; Cyril Breuker; Laetitia Zerkowski; Simon Letertre; Cédric Mercuzot; Jonathan Bigot; Guilhem Du Cailar; François Roubille; Pierre Fesler Journal: Intern Emerg Med Date: 2022-04-22 Impact factor: 5.472
Authors: Marc N Hirt; Aljosha Muttardi; Thomas M Helms; Hendrik van den Bussche; Thomas Eschenhagen Journal: Clin Res Cardiol Date: 2015-11-09 Impact factor: 5.460
Authors: M Arcopinto; A Salzano; F Ferrara; E Bobbio; A M Marra; R Abete; F Stagnaro; R Polizzi; F Giallauria; M Illario; E Menditto; C Vigorito; E Bossone; A Cittadini Journal: Transl Med UniSa Date: 2016-05-16
Authors: Ramon F Abarquez; Paul Ferdinand M Reganit; Carmen N Chungunco; Jean Alcover; Felix Eduardo R Punzalan; Eugenio B Reyes; Elleen L Cunanan Journal: ASEAN Heart J Date: 2016-03-08
Authors: Caroline Morbach; Martin Wagner; Stefan Güntner; Carolin Malsch; Mehmet Oezkur; David Wood; Kornelia Kotseva; Rainer Leyh; Georg Ertl; Wolfgang Karmann; Peter U Heuschmann; Stefan Störk Journal: BMC Cardiovasc Disord Date: 2017-05-05 Impact factor: 2.298